Prior to breast cancer treatment, one-third of patients already used cardioprotective drugs, either angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers (BBs), or statins, for their cardiovascular conditions. This evidence concerns the gene ACE and breast cancer.